ReviewPrecise protein conjugation technology for the construction of homogenous glycovaccines
Graphical abstract
Introduction
Vaccines are one of the most important tools in our fight against various infectious diseases. As resistance against many antibiotics increases and new viruses appear, the development of new vaccine candidates becomes ever more important. Glycoconjugate vaccines represent one of the most successful strategies to elicit a strong and long-lasting immune response, especially in infants. In general, the conjugation of a polysaccharide antigen to an immunogenic protein carrier generates a T-cell dependent immune response, which leads to the formation of enduring memory B-cells [1], [2]. By following this approach, glycoconjugate vaccines have been licensed for a number of infectious diseases, such as Haemophilus influenzae type b, Samonella Typhi, Neisseria meningitidis and Streptococcus pneumoniae [3], [4].
In recent years, efforts have been made to understand the exact mechanism by which glycoconjugates are processed by the immune system, and to develop more defined vaccine constructs. So far, glycoconjugate vaccines have been obtained largely through random conjugation reactions of polysaccharide antigens to immunogenic protein carriers [3], [5]. These reactions, like reductive aminations, active esters or carbodiimide-mediated couplings, commonly take place on functionalities of the carbohydrate or through the installation of a linker moiety between the sugar and a different amino acid, typically lysine, aspartic or glutamic residues, on the carrier protein (Fig. 1, I–III) [6]. Currently, there are six carrier proteins being used for licensed vaccines, namely tetanus toxoid (TT), diphtheria toxoid, CRM197, recombinant exotoxin A of P.aeruginosa, Protein D from H. influenzae and the outer membrane protein complex of meningococcus B. Despite the efficiency of the resulting constructs, the current approach comes with drawbacks like batch-to-batch variations and rather undefined products. To overcome these problems, new methods have been developed for the chemical synthesis of desired glycan antigens and for their site-selective conjugation on the protein carrier. The goal of a defined site-selective conjugation on a carrier can be addressed in different ways and we highlight some of them here, together with recent examples of chemically-defined glycoconjugate constructs.
Section snippets
Fully synthetic conjugate – Quimi-hib
The biggest success in synthetic glycoconjugate vaccine design so far is arguably the fully synthetic glycoconjugate vaccine Quimi-Hib against Haemophilus influenza type b in 2004 [7]. The authors identified four key points that facilitated the successful production of this defined glycoconjugate vaccine on a large scale: a synthetic route for a precursor disaccharide with just one chromatographic purification step, a high-yielding polycondensation reaction to obtain the necessary
Site-selective protein modification – non-canonical amino acids
There are a number of different routes available when it comes to the development of new site-selective modification strategies. The options include modifying proteinogenic amino acids, as in the selective glycoconjugates examples above, or introducing non-canonical amino acids. The use of non-canonical amino acids for modification reactions brings the advantage of new functional groups and usually minimizes unwanted side reactions [14]. A range of technologies introduce non-canonical amino
Selective lysine conjugates
Lysine represents the most abundant amino acid residue in carrier proteins like CRM197 or TT and presents a nucleophilic ε-amine sidechain. However, the high reactivity makes site-selective reactions on this sidechain particularly challenging and difficult to control. Nevertheless, methods have been developed to discriminate different lysine residues based on their reactivity and to use this differentiation for selective conjugations. Crotti et al. were able to map 37 of 39 lysine residues of
Effects of protein modification on function and immunogenicity of glycoconjugate vaccines [42]
The conjugation of carbohydrate antigens towards immunogenic protein carriers is a key point to enable the generation of polysaccharide specific IgG antibodies and the development of long-lasting T-cells [2], [43]. Although the exact mechanism of glycoconjugate vaccines in terms of immune recognition is little understood, different factors are known to influence the immunogenicity of these constructs. Length and density of the carbohydrate antigen, together with the conjugation method to the
Concluding remarks
These exemplary studies demonstrate the importance of site-selective conjugation for the development of efficient vaccine candidates. Ongoing research to introduce defined modifications in potential carrier proteins may provide useful tools on the road to a fully synthetic and defined conjugate vaccine. As bacterial resistance to current antibiotic treatments increases and new viruses emerge, vaccines will be crucial in our fight against them.
Conflict of interest
The authors declare that they have no conflict of interest.
Acknowledgements
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 675671 (A.K. and G.J.L.B.). Funding from the Royal Society (URFR180019 to G.J.L.B.), FCT Portugal (iFCT IF/00624/2015 to G.J.L.B.) and Agencia Estatal Investigacion of Spain (AEI; RTI2018-099592-B-C21 project to F.C.) is also acknowledged. We also thank Dr Vikki Cantrill for her help with the editing of this manuscript.
References (45)
- et al.
Site-specific glycoconjugation of protein via bioorthogonal tetrazine cycloaddition with a genetically encoded trans-cyclooctene or bicyclononyne
Bioconjugate Chem
(2015) - et al.
Synthesis of azido-glycans for chemical glycomodification of proteins
Eur. J. Org. Chem. 2018
(2018) - et al.
Exploring the effect of conjugation site and chemistry on the immunogenicity of an anti-group B Streptococcus glycoconjugate vaccine based on GBS67 pilus protein and type v polysaccharide
Bioconjugate Chem
(2015) - et al.
Water-soluble allyl sulfones for dual site-specific labelling of proteins and cyclic peptides
Chem Sci
(2016) - et al.
A general approach for the site-selective modification of native proteins, enabling the generation of stable and functional antibody–drug conjugates
Chem Sci
(2019) Glycoconjugate vaccines: principles and mechanisms
Sci Transl Med
(2018)- et al.
A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design
Nat Med
(2011) - et al.
Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches for protein modification
Chem Soc Rev
(2018) - et al.
Glycoconjugate vaccines: current approaches towards faster vaccine design
Expert Rev. Vaccines
(2019) - et al.
Synthetically defined glycoprotein vaccines: current status and future directions
Chem Sci
(2013)